SP Advises Mentice AB on Add-on Acquisition
SP advises Mentice in acquiring Endovascular Business from Medical Simulation Corp.
Mentice AB, headquartered in Gothenburg, Sweden, boosts its US development presence and adds a clinical training service line with the acquisition of Medical Simulation Corporation’s (MSC) Medical Products division. Mentice is the global leader of simulation-based performance solutions for endovascular therapies. Sonenshine Partners served as the investment banking adviser to Mentice on the transaction.
Under the agreement, Mentice has acquired the assets of MSC’s Medical Products division in a share based transaction.
“With this transaction Mentice gains a very experienced US-based development organization, supporting our North American customers along with a portfolio of solutions that will be leveraged in the Mentice VIST® product line,” says Goran Malmberg, CEO of Mentice. “Furthermore, we are adding clinical training services, providing our clients with an even wider choice of offerings. I believe this will greatly benefit both our current and new customers, clearly demonstrating Mentice’s commitment in taking the market to the next level.”
Mentice will immediately assume responsibility for MSC’s clients and will provide continued support for the Compass AT and Compass 2 platforms along with associated software and iPad Apps. Mentice also plans to offer migration solutions to the Mentice VIST platform.
Sonenshine Partners, with offices in New York and London, has been a leading M&A advisor on Medical Simulation and General Simulation transactions globally. In the medical simulation arena, the Firm has advised on such notable transactions as the merger of Simbionix with 3D Systems and the public listing of Surgical Science Sweden AB. In the general simulation arena, the firm has advised on numerous mergers with companies such as Simulia, Real Time Technology and Dassault Systemes SA.
Chris Reenock, Vice President at Sonenshine Partners, noted, “Our firm has long been committed to clients whose businesses improve healthcare delivery and patient outcomes. Mentice is a perfect example of excellence in these domains, and this transaction serves to solidify the company’s leadership in its field.”
Goran Malmberg, Mentice’s CEO, said, “We are so pleased to have been advised by Sonenshine Partners given the firm’s leadership as M&A advisers and its unparalleled expertise in our industry.”
Mentice is the world leader in virtual reality-based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and pre-procedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated, and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. Learn more about the features and benefits of Mentice solutions at: www.mentice.com.
About MSC (Medical Simulation Corporation)
MSC is a global healthcare leader in accelerating patient access to new medical therapies, achieving the best patient outcomes, reducing patient mortality and reducing the cost of healthcare delivery. MSC’s Advanced Clinical Quality Solutions enable multi-disciplinary healthcare team performance improvement, with a focus on standardizing care delivery and creating clinical and cost-control results. For further info please visit www.medsimulation.com.
About Sonenshine Partners
Established in 2000, Sonenshine Partners is a private investment bank advising major companies worldwide on mergers, acquisitions, corporate finance and restructuring transactions across multiple industry sectors. With offices in New York and London, Sonenshine Partners brings unique insights, unconflicted advice and extensive dealmaking experience to its global client base.